32results about How to "Efficient therapeutic effect" patented technology

The invention discloses an interface-cross-linked temperature-sensitive polymer vesicle and a method for preparing the same. The interface-cross-linked temperature-sensitive polymer vesicle is formed by a block copolymer which at least comprises a hydrophilic block, a cross-lined interstrand block and a temperature sensitive block, wherein the hydrophilic block forms the membrane shell of the polymer vesicle, the temperature sensitive block forms the membrane nuclear of the polymer vesicle, and the cross-lined interstrand block forms the interface of the polymer vesicle to cross-link the interface of the polymer vesicle to stabilize the structure of the vesicle, and thus the interface-cross-linked temperature-sensitive polymer vesicle is formed; as the vesicle is formed in an aqueous solution system and the interface of vesicle is cross-linked, the small molecule drug, macromolecular drug and probe molecule entrapment efficiency of the polymer vesicle, the circulation stability in vivo blood and the efficiency of endocytosis by tumor cells are improved; and as a result, the bioavailability of drugs is improved and the polymer vesicle can be expelled out of the body conveniently.

The invention relates to preparation and application of a reducing sensitive nano-micelle, belonging to preparation and application of an amphiphilic block polymer. A hydrophilic section and a hydrophobic section of the amphiphilic block polymer are connected with each other by a reducing responsive sulfur-sulfur bond; the nano-micelle is formed by self-assembling; the reducing sensitive nano-micelle consists of a shell and an inner core, wherein the shell is a hydrophilic polymer, and the inner core is a hydrophobic polymer; the hydrophilic section of the amphiphilic block polymer is polyphosphate, the hydrophobic section of the amphiphilic block polymer is poly(benzyl glutamate), and the hydrophilic section and the hydrophobic section of the amphiphilic block polymer are connected with each other by the reducing responsive sulfur-sulfur bond. The reducing sensitive nano-micelle has the advantages that the drug-loaded nano-micelle is difficult to dissociate outside the cells or in the blood, so that the drug encapsulated in the nano-micelle is enabled to be stable; once the nano-micelle enters the cancer cell, the sulfur-sulfur bond can be disconnected by glutathione which is a reducing matter in the cell, so that the nano-micelle is rapidly dissociated, the anti-cancer drug encapsulated in the nano-micelle can be rapidly and effectively released out, and an effective treatment effect is achieved; the reducing sensitive nano-micelle overcomes the defects that the drug is easy to leak in vivo, low in transport efficiency, slow in intracellular release speed, and the like.

The invention discloses a thioctic acid-modified hydrophilic polymer for a side chain, a preparation method thereof and application thereof. The thioctic acid-modified hydrophilic polymer is an amphiphilic polymer, wherein the main chain of the amphiphilic polymer is the hydrophilic polymer; the side chain is a thioctic acyl; and the thioctic acyl is condensed with a hydroxyl or an amido in the hydrophilic polymer to form an ester bond or an amido bond. Nano particles formed by self-assembly of the amphiphilic polymer can be cross-linked to obtain stable cross-linked polymer nano particles which are sensitive to reduction, so the nano particles are not easy to disaggregate outside cells or in blood and then a medicament wrapped by the nano particles is ensured to be stable; once entering a tumor cell, the nano particles are quickly de-cross-linked to be disaggregated, so the medicament are quickly released and a high-efficiency treatment effect is achieved; and the disadvantages of easiness in leakage of the medicament in vivo, low carrying efficiency, slow release in cells and the like are overcome.

The invention discloses a hydrophilic polymer the side chain of which is modified by lipoic acid and preparation and application thereof. The hydrophilic polymer the side chain of which is modified bylipoic acid is an amphipathic polymer; the main chain of the amphipathic polymer is an hydrophilic polymer, and the side chain is a lipoic acid radical; the lipoic acid radical and a hydroxide radical or an amino group in the hydrophilic polymer are condensed to form an ester bond or an acidamide bond; crosslinking can be carried out by nano particles formed by the self assembly of the amphipathic polymer to obtain stable crosslinking polymer nano particles with sensitive reduction, so that the nano particles are not easy to dissociate both outside cells and in blood, thereby ensuring the stability of drugs encapsulated by the nano particles; the nano particles rapidly relieve crosslinking to dissociate once entering tumor cells, and then the drugs rapidly release to generate the high-efficiency therapeutic effect. The deficiencies that the drugs are easy to leak, the carrying efficiency is low, the release speed in the cells is slow and the like are solved.

The invention discloses a preparation method and use of a thioctic acid-modified polyethylene glycol-polyaminoacid amphiphilic triblock copolymer. A hydrophilic chain of the amphipathic triblock polymer is polyethylene glycol, a middle hydrophobic chain segment of the amphipathic triblock polymer is poly(benzyl glutamate), a tail hydrophobic chain segment of the amphipathic triblock polymer is polyphenylalanine and the side chain of the middle chain segment is modified through thioctic acid. The amphipathic triblock polymer is self-assembled in water to form a polymer nanometer micelle with polyethylene glycol as an outer crown, thioctic acid-modified poly(benzyl glutamate) as a middle shell and polyphenylalanine as an inner core. Through crosslinking of the nanometer micelle, the stable reduction-sensitive shell crosslinked nanometer micelle is obtained so that the nanometer micelle is not easily dissociated in vitro and in blood and thus stability of a nanometer micelle-coated drug is guaranteed. When the nanometer micelle enters a tumor cell, the nanometer micelle can be fast crosslinked and dissociated so that the drug can be fast released and produces high treatment effects. The amphipathic triblock polymer solves the problems of drug leakage in vivo, low conveying efficiency and slow release in cells.

The invention discloses a synthesis method and use of a cholic acid-modified polyamino acid block copolymer. A hydrophilic chain of the block copolymer is polyethylene glycol, a hydrophobic chain of the block copolymer is polyamino acid, the tail end of the polyamino acid is modified through micromolecular cholic acid, the side chain of the polyamino acid is a lipoyl group, and lipoic acid and an amino group of hydrophobic polyamino acid undergo a reaction to produce an amido bond. Through crosslinking of a self-assembled nanometer micelle of the cholic acid-modified polyamino acid block copolymer, a stable crosslinked reduction-sensitive polymer nanometer micelle is obtained so that the nanometer micelle is not easily damaged in vitro and in blood and nanometer micelle-coated drug stability is guaranteed. When the nanometer micelle enters a cancer cell, the nanometer micelle can be fast decrosslinked and dissociated and the coated drug can be fast released and produce high efficiency treatment effects. The cholic acid-modified polyamino acid block copolymer solves the problems of early release of a drug in vivo, low carrying efficiency and a slow release rate in cells.

The invention discloses a compound dimetridazole premix for preventing and treating the poultry enterovirus syndrome. The premix is prepared by uniformly mixing the following components in percentage by weight: 10 to 30 percent of dimetridazole, 4 to 10 percent of neomycin sulfate, 2 to 8 percent of decoquinate econazole nitrate, 10 to 30 percent of lysozyme, 0.5 to 5 percent of etamsylate, 3 to 10 percent of lactic acid TMP and the balance of pharmaceutically applicable auxiliary material. According to the invention, the novel high-efficiency anticoccidial drug decoquinate econazole nitrate, the dimetridazole and the neomycin sulfate which have a special curative effect on intestinal infection, the lysozyme with effects of resisting to bacteria, resisting to viruses, diminishing inflammation, relieving pain and repairing intestinal mucosa, the high-efficiency hemostatics etamsylate and the drug synergist are compounded into a compound preparation; and the compound dimetridazole premix has a high-efficiency treatment effect on the poultry enterovirus syndrome. The compound dimetridazole premix has a reasonable and scientific formula, is simple to prepare, has wide application and can be used as a priority drug for preventing and treating the poultry enterovirus syndrome.

The invention relates to compound soluble powder for treating respiratory diseases of birds. The compound soluble powder is prepared by mixing the following components by taking 100g as unit weight: 5-20g of tylosin tartrate, 10-30g of doxycycline hydrochloride, 5-10g of ribavirin, 5-20g of N- acetylcysteine, 2-5g of epidermal growth factor, and the balance of pharmaceutically applicable auxiliary material. The pharmaceutically applicable auxiliary material is anhydrous dextrose or oral glucose, and is preferably the anhydrous dextrose. The invention adopts a compound preparation combining antibiotic medicaments, antivirus medicaments, expectorants and the epidermal growth factor and can effectively and fast treat the respiratory diseases of birds. The invention has the advantages of simple preparation, remarkable effect and wide application.

The invention relates to a compound preparation for preventing and treating respiratory diseases of livestock and poultry, which is characterized by being prepared by uniformly mixing the following components by taking 100 grams as unit weight: 2-5 grams of cefixime sodium, 10-30 grams of doxycycline hydrochloride, 5-10 grams of rifampicin, 5-20 grams of cimetidine, 2-10 grams of ndometacin sodium, 2-6 grams of propolis powder, 2-6 grams of muramyl dipeptide and the balance of pharmaceutically applicable auxiliary materials, wherein the pharmaceutically applicable auxiliary materials are anhydrous glucose or oral glucose, preferably the anhydrous glucose. The compound preparation is compounded by antibiotic drugs, antiviral drugs, immunopotentiator and mucosa repair factors and has efficient and fast cure effect on respiratory symptoms of the livestock and the poultry, easy preparation, obvious effect and wide application range.

The invention discloses a preparation method and application of intelligent responsive shell-core polyelectrolyte nanogel. The nanogel is composed of a shell layer of hyaluronic acid or derivatives and analogues thereof and a core layer of ligand modified hyperbranched polyethyleneimine formed by crosslinking glutathione sensitive or acid sensitive crosslinking agents, and the hyaluronic acid shell and the hyperbranched polyethyleneimine core are connected by a tumor microenvironment sensitive crosslinking agent through a click chemical reaction to form the intelligent responsive shell-core nanogel. The nanogel can entrap a variety of hydrophilic and hydrophobic drugs or proteins containing electricity due to the electrification, and contains a variety of tumor microenvironment responsive crosslinking agents, can respond to tumor sites and quickly release the drugs entrapped by the nanogel, thus achieving an efficient anti-tumor effect.

Temozolomide prodrug nano-micelles each comprise a hydrophilic shell and a hydrophobic core; each hydrophilic shell is polyoxazoline or polyethylene glycol, and the hydrophobic cores are each polytemozolomide. A preparation method for the temozolomide prodrug nano-micelles is characterized in that the polyoxazoline or polyethylene glycol reacts with 4-cyano-4-valeric acid through an esterificationreaction, and as a macromolecular reversible addition-fragmentation chain transfer polymerization (RAFT) reagent, an obtained product reacts with temozolomide-methyl methacrylate under catalysis of azodiisobutyronitrile to obtain amphiphilic block polymers. According to the temozolomide prodrug nano-micelles, the amphiphilic block polymers can extend the half-life period of temozolomide; two amphiphilic block polymer nano-micelles both belong to the prodrugs of the temozolomide, and meanwhile, the cores of the micelles can entrap other anticancer drugs to realize combination therapy of different drugs. After entering a tumor cell, the polyoxazoline-polytemozolomide micelles crack in the acidic environment of the cancer cell, and encapsulated drugs are quickly released, and thereby, a high-efficiency therapeutic effect is generated, and the problems that a drug carrier is slow in drug release, and is prone to be drug-resistant are solved.

The invention discloses an amphiphilic graft copolymer and application thereof, belonging to the technical field of pharmaceutical preparations. The amphiphilic graft copolymer comprises a hydrophilicpolymer, wherein an amphiphilic short chain containing an imidazole group is modified on a skeleton of the hydrophilic polymer. The amphiphilic graft copolymer provided by the invention has an amphiphilic short chain containing an imidazole group, so reversible morphological change can be generated in response to pH change, and a micelle structure is formed by self-assembly in a neutral or alkaline environment; in an acid environment, micelle is disintegrated and exists in a stretched chain structure form; and when the micelle is disintegrated and enters a neutral or alkaline environment again, the micelle can be self-assembled again to form the micelle structure.

The invention discloses a preparation method and use of a thioctic acid-modified polyethylene glycol-polyaminoacid amphiphilic triblock copolymer. A hydrophilic chain of the amphipathic triblock polymer is polyethylene glycol, a middle hydrophobic chain segment of the amphipathic triblock polymer is poly(benzyl glutamate), a tail hydrophobic chain segment of the amphipathic triblock polymer is polyphenylalanine and the side chain of the middle chain segment is modified through thioctic acid. The amphipathic triblock polymer is self-assembled in water to form a polymer nanometer micelle with polyethylene glycol as an outer crown, thioctic acid-modified poly(benzyl glutamate) as a middle shell and polyphenylalanine as an inner core. Through crosslinking of the nanometer micelle, the stable reduction-sensitive shell crosslinked nanometer micelle is obtained so that the nanometer micelle is not easily dissociated in vitro and in blood and thus stability of a nanometer micelle-coated drug is guaranteed. When the nanometer micelle enters a tumor cell, the nanometer micelle can be fast crosslinked and dissociated so that the drug can be fast released and produces high treatment effects. The amphipathic triblock polymer solves the problems of drug leakage in vivo, low conveying efficiency and slow release in cells.

The invention discloses a traditional Chinese medicine composition and a preparing method, application and preparation thereof. The traditional Chinese medicine composition is prepared form, by weight, 3-75 parts of herba epimedii, 5-125 parts of centella asiatica, 4-100 parts of radix achyranthis bidentatae and 4-100 parts of bighead atractylodes rhizome. It is proved by pharmacological researches that the traditional Chinese medicine composition can obviously relieve prostate tissue lesions degree of prostatitis rats, remarkably reduce the number of prostate white blood cells, increase the intensity of prostate lecithin corpuscle and has a good therapeutical effect on the prostatitis. Raw materials of the traditional Chinese medicine composition are easy to obtain, the preparing method is scientific, clear in material basis, definite in pharmacological effect and mechanism, capable of treating both symptoms and root causes of the prostatitis and has wide application prospects.

The invention discloses a thioctic acid-modified hydrophilic polymer for a side chain, a preparation method thereof and application thereof. The thioctic acid-modified hydrophilic polymer is an amphiphilic polymer, wherein the main chain of the amphiphilic polymer is the hydrophilic polymer; the side chain is a thioctic acyl; and the thioctic acyl is condensed with a hydroxyl or an amido in the hydrophilic polymer to form an ester bond or an amido bond. Nano particles formed by self-assembly of the amphiphilic polymer can be cross-linked to obtain stable cross-linked polymer nano particles which are sensitive to reduction, so the nano particles are not easy to disaggregate outside cells or in blood and then a medicament wrapped by the nano particles is ensured to be stable; once entering a tumor cell, the nano particles are quickly de-cross-linked to be disaggregated, so the medicament are quickly released and a high-efficiency treatment effect is achieved; and the disadvantages of easiness in leakage of the medicament in vivo, low carrying efficiency, slow release in cells and the like are overcome.

The invention relates to a Tibetan medicine compound for treating calf diarrhea and a preparation method thereof, and relates to the technical field of medicines. The Tibetan medicine compound is prepared from the following raw materials in parts by weight: 1-3 parts of barberry root, 1-4 parts of hippophae rhamnoides, 5 parts of myrobalan, 2 parts of dracocephalum tanguticum and 2 parts of corydalis pygmaea. The Tibetan medicine compound disclosed by the invention has the effects of inhibiting bacteria, stopping diarrhea and easing pain, also has the effect of reducing intestinal advancement rate, inhibits intestinal epithelial cell shedding, reduces mucosal edema, reduces inflammatory cell infiltration, promotes rapid healing of diarrhea, does not easily generate bacterial drug resistance, and does not influence animal production performance.

The invention provides preparation and application of a cytarabine-modified methotrexate-loaded liposome. The liposome is prepared by taking phospholipid, cholesterol, cytarabine-PEG2k-DSPE and methotrexate as raw materials and adopting a membrane dispersion method combined with an ultrasonic and high-pressure homogenization method through dissolution, membrane formation, hydration, ultrasonic andhigh-pressure homogenization and freeze-drying. The liposome prepared by the method has a particle diameter of about 125 nanometers, a dispersion coefficient of 0.218, a drug loading capacity of themethotrexate of about 10.37% and an entrapment ratio of about 85.26%. Nucleoside transporters 1 on the surfaces of choriocarcinoma cells can specifically recognize cytarabine and mediate the cytarabine-modified methotrexate-loaded liposome into the cells, thereby increasing the cytotoxicity of the drug. The cytarabine-modified methotrexate-loaded liposome has a simple preparation process, is easyto produce on a large scale, and provides a novel pharmaceutical preparation for the treatment of choriocarcinoma.

The invention discloses an antibacterial polypeptide compound, a medical device, hydrogel and application thereof. The antibacterial polypeptide compound has high antibacterial activity, high enzymolysis stability, high bioavailability and low cytotoxicity. The hydrogel does not adhere to wounds, has antibacterial activity and hemostatic performance, and can be used for drug entrapment and slow release, for example, anti-inflammatory drugs or epidermal growth factors, angiogenesis factors and the like can be loaded, wound healing is accelerated, and formation of scar tissue fibers is reduced. Meanwhile, the preparation method of the hydrogel is few in process steps, simple in raw material variety and convenient to operate.

The invention discloses an interface-cross-linked temperature-sensitive polymer vesicle and a method for preparing the same. The interface-cross-linked temperature-sensitive polymer vesicle is formed The invention discloses an interface-cross-linked temperature-sensitive polymer vesicle and a method for preparing the same. The interface-cross-linked temperature-sensitive polymer vesicle is formedby a block copolymer which at least comprises a hydrophilic block, a cross-lined interstrand block and a temperature sensitive block, wherein the hydrophilic block forms the membrane shell of the polyby a block copolymer which at least comprises a hydrophilic block, a cross-lined interstrand block and a temperature sensitive block, wherein the hydrophilic block forms the membrane shell of the polymer vesicle, the temperature sensitive block forms the membrane nuclear of the polymer vesicle, and the cross-lined interstrand block forms the interface of the polymer vesicle to cross-link the intermer vesicle, the temperature sensitive block forms the membrane nuclear of the polymer vesicle, and the cross-lined interstrand block forms the interface of the polymer vesicle to cross-link the interface of the polymer vesicle to stabilize the structure of the vesicle, and thus the interface-cross-linked temperature-sensitive polymer vesicle is formed; as the vesicle is formed in an aqueous solutface of the polymer vesicle to stabilize the structure of the vesicle, and thus the interface-cross-linked temperature-sensitive polymer vesicle is formed; as the vesicle is formed in an aqueous solution system and the interface of vesicle is cross-linked, the small molecule drug, macromolecular drug and probe molecule entrapment efficiency of the polymer vesicle, the circulation stability in vivoion system and the interface of vesicle is cross-linked, the small molecule drug, macromolecular drug and probe molecule entrapment efficiency of the polymer vesicle, the circulation stability in vivo blood and the efficiency of endocytosis by tumor cells are improved; and as a result, the bioavailability of drugs is improved and the polymer vesicle can be expelled out of the body conveniently.blood and the efficiency of endocytosis by tumor cells are improved; and as a result, the bioavailability of drugs is improved and the polymer vesicle can be expelled out of the body conveniently.

The invention relates to a Tibetan medicine compound for treating calf gastrointestinal diseases and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The Tibetan medicine compound is prepared from the following raw materials in parts by weight: 1 to 3 parts of berberis julianae schneid, 1 to 3 parts of herba elsholtziae, 1 to 5 parts of radix gentianae macrophyllae, 2 parts of fructus chebulae, 1 part of herba dracocephali tangutici and 1 part of herba corydalis. The Tibetan medicine compound provided by the invention has the effects of inhibiting bacteria, stopping diarrhea and easing pain, and also has the effect of reducing the intestinal propulsion rate; the intestinal epithelial cell falling is inhibited; the mucosal edema is reduced; the inflammatory cell infiltration is reduced; the fast healing of diarrhea is promoted; the bacterial drug resistance cannot be easily generated; and the animal production performance is not influenced.

The invention belongs to the field of biological pharmacy, and relates to a nano medicine drug for liver-related diseases as well as a preparation method and an application of the nano gene drug, andthe nano gene medicine is formed by taking polyamide-amine dendrimer (PAMAM 3.0), DSPE-PEG2000 and penetratin as carriers and performing self-assembly on the carriers and anion therapy genes. The nano-gene medicine can target liver parenchyma cells and generate a therapeutic effect by overexpression or interference of synthesis of certain proteins. The invention also provides a preparation methodof the nano gene medicine. The nano gene medicine has the characteristics of high stability, controllable quality and relative safety. The nano gene medicine can remarkably protect liver cells from being damaged, and is expected to become a medicine for protecting liver cells from being damaged.